Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer
Background and objective Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that selectively binds to and neutralizes the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab was approved by the U.S. Food and Drug Administration (FDA) in October 2006 for use...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2009-03-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2009.03.006&path%5B%5D=250 |